Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01571232 · ClinicalTrials.gov registry record · Phase 2

Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema

A Phase 2 study, sponsored by Retina Macula Institute.

Completed
Registry status
Phase 2
Development phase
20
Enrollment target

NCT01571232: Completed Phase 2 study, sponsored by Retina Macula Institute.

NCT01571232 is a Phase 2 study that has completed, run by Retina Macula Institute. The registered enrollment target is 20 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT01571232, a Phase 2 study, has completed, sponsored by Retina Macula Institute.

COMPLETED
Registry status
Phase 2
Development phase
20 participants
Enrollment target

Study Summary

The purpose of this study is to test the efficacy of an 0.7 mg intravitreal dexamethasone implant (Ozurdex®) on macular leakage and visual acuity for patients with recalcitrant diabetic macular edema.

Primary Outcome

The measure the change in ETDRS letters for each treatment group from baseline to 6 months.

Interventions

  • DRUG dexamethasone intravitreal implant
  • DRUG intravitreal bevacizumab

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2012-04
Est. Completion 2015-03
Phase Phase 2
Retina Macula Institute

3 total trials

What the finished NCT01571232 record still lists

NCT01571232 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower).

The record links to 0 conditions, and to 2 interventions - of which dexamethasone intravitreal implant is the first listed.

NCT01571232 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01571232 about?

NCT01571232 is a clinical study titled "Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema". The purpose of this study is to test the efficacy of an 0.7 mg intravitreal dexamethasone implant (Ozurdex®) on macular leakage and visual acuity for patients with recalcitrant diabetic macular edema.

What is the current status of trial NCT01571232?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2012-04. Estimated completion is 2015-03.

What interventions are being tested in trial NCT01571232?

The interventions under investigation include: dexamethasone intravitreal implant (DRUG), intravitreal bevacizumab (DRUG).

Who is sponsoring clinical trial NCT01571232?

This trial is sponsored by Retina Macula Institute, which has 3 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01571232's enrollment target sits among peer trials

20 1805th of 2000 higher than 107 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01571232, the US trial registry maintained by the National Library of Medicine. NCT01571232 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.